TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25286913

Group type: EXPERIMENTAL
Intervention: Hemodynamically guided HF management using daily uploaded pressures
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Hemodynamically guided HF management
Number of subjects: 550

Group type: COMPARATOR
Intervention: Standard HF management (control group)
Number of subjects: 550
Study: 22311517

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Estrogen
Number of subjects: 25

Group type: COMPARATOR
Intervention: PTH(1‐34) infusion
Number of subjects: 25
Study: 20835586

Group type: EXPERIMENTAL
Intervention: Multiple-dose inhaler (400 µg of MF once a day for 60 days)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Single-dose inhaler (400 µg of MF once a day for 60 days)
Number of subjects: 74
Study: 17617901

Group type: EXPERIMENTAL
Intervention: Selenium as sodium selenite (4,000 microg on the first day, 1,000 microg/day for the next 9 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Selenium as sodium selenite
Number of subjects: 60
Study: 16076379

Group type: EXPERIMENTAL
Intervention: Sevelamer 6.0 g/day (Group A)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Sevelamer 3.0 g/day and Calcium Carbonate 3.0 g/day (Group B)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Calcium Carbonate 3.0 g/day (Group C)
Number of subjects: 62
Study: 12163427

Group type: EXPERIMENTAL
Intervention: Rosiglitazone treatment
Number of subjects: 0
Study: 10450630

Group type: EXPERIMENTAL
Intervention: Full Cognitive Therapy (FCT)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Brief Cognitive Therapy (BCT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Wait list
Number of subjects: 43
Study: 7846788

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium
Number of subjects: 2438

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 2438
Study: 31228015

Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention
Number of subjects: 151
Study: 30153598

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg ketamine
Number of subjects: 71

Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 71
Study: 27427877

Group type: EXPERIMENTAL
Intervention: Influenza/hepatitis B vaccination
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Pneumococcus/hepatitis B vaccination
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Vaccination (combined effects)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 24630742

Group type: EXPERIMENTAL
Intervention: Primary negative symptoms
Number of subjects: 1427
Study: 22362720

Group type: EXPERIMENTAL
Intervention: Suckling on a pacifier incorporated into a mask
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional mask
Number of subjects: 12
Study: 19827463

Group type: EXPERIMENTAL
Intervention: Encapsulated antioxidant concentrate (EAC)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 17719303

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 264

Group type: COMPARATOR
Intervention: Sodium chloride alone
Number of subjects: 264

Group type: COMPARATOR
Intervention: Sodium chloride plus oral NAC (600 mg bid)
Number of subjects: 264
Study: 15212623

Group type: COMPARATOR
Intervention: Strontium ranelate 1000 mg/day
Number of subjects: 353

Group type: COMPARATOR
Intervention: Strontium ranelate 2000 mg/day
Number of subjects: 353

Group type: COMPARATOR
Intervention: Strontium ranelate 2000 mg
Number of subjects: 353

Group type: COMPARATOR
Intervention: Strontium ranelate
Number of subjects: 353
Study: 11456285

Group type: EXPERIMENTAL
Intervention: Glycine 5 g orally
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9604941

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 94

Group type: COMPARATOR
Intervention: No Aspirin
Number of subjects: 94
Study: 7809344

Group type: EXPERIMENTAL
Intervention: Short-term cognitive psychotherapy (10 sessions during 4 months)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no psychotherapy)
Number of subjects: 100
Study: 3044870

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (300 mg: 100 mg twice a day orally and 100 mg suppository at night)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diclofenac sodium (75 mg: 25 mg twice daily orally and 25 mg suppository at night)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 40
Study: 31786746

Group type: EXPERIMENTAL
Intervention: Barbed repositioning pharyngoplasty (BRP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study: 29488900

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerine (0.4 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Inorganic nitrate (beetroot juice, 12.9 mmol NO3)
Number of subjects: 42
Study: 28415999

Group type: EXPERIMENTAL
Intervention: TALKING TIME intervention (telephone-based support groups)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 88
Study: 25171664

Group type: EXPERIMENTAL
Intervention: W40 (40% of maximal isometric voluntary contraction)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: W70 (70% of maximal isometric voluntary contraction)
Number of subjects: 20

Group type: COMPARATOR
Intervention: W40
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: W70
Number of subjects: 20
Study: 23910206

Group type: EXPERIMENTAL
Intervention: 5 mm miniscrews
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 6 mm miniscrews
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 7 mm miniscrews
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Miniscrews placed with insertion torque greater than 10 Ncm
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Miniscrews placed in less than approximately 3.8 mm of bone
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Miniscrews placed within 1.4 mm of the root
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Miniscrews in the maxilla
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Miniscrews in the mandible
Number of subjects: 105
Study: 21951683

Group type: EXPERIMENTAL
Intervention: Autologous peripheral blood stem cell transplantation (ASCT) after high-dose cyclophosphamide and busulfan
Number of subjects: 517

Group type: COMPARATOR
Intervention: Intensive chemotherapy with etoposide and mitoxantrone
Number of subjects: 517

Group type: COMPARATOR
Intervention: Overall survival
Number of subjects: 517
Study: 19027413

Group type: EXPERIMENTAL
Intervention: Enhanced energy density lunch meal
Number of subjects: 45

Group type: COMPARATOR
Intervention: Regular lunch meal
Number of subjects: 45
Study: 16634339

Group type: EXPERIMENTAL
Intervention: Supervised training
Number of subjects: 47

Group type: COMPARATOR
Intervention: Home training
Number of subjects: 47
Study: 12537035

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (no tryptophan)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (nutritionally balanced drink containing tryptophan)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 11082469

Group type: EXPERIMENTAL
Intervention: Active TMS (20 subjects)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham (10 subjects)
Number of subjects: 30
Study: 8705395

Group type: EXPERIMENTAL
Intervention: rBPI23 administered as a 5 or 30 min infusion at doses of 0.1 to 1 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rBPI23
Number of subjects: 0
Study: 1510645

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg, twice daily)
Number of subjects: 7
Study: 6611245

Group type: EXPERIMENTAL
Intervention: Bicycle ergometry
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Short walks
Number of subjects: 46
Study: 30415354

Group type: EXPERIMENTAL
Intervention: Amoxicillin 500 mg capsule orally before RYGB surgery
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Amoxicillin 500 mg capsule orally 2 months after RYGB surgery
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Amoxicillin 500 mg capsule orally before and after RYGB surgery
Number of subjects: 8
Study: 30541506

Group type: EXPERIMENTAL
Intervention: Insulin plus metformin
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Insulin plus placebo
Number of subjects: 1200
Study: 28119757

Group type: EXPERIMENTAL
Intervention: TAT-SOD applied to acupoints LI 20
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (vehicle cream)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TAT-SOD applied directly to nasal cavity (TTN group)
Number of subjects: 0
Study: 24454728

Group type: EXPERIMENTAL
Intervention: Universal ART provision in arm A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ART according to national guidelines in arm B
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm C
Number of subjects: 0
Study: 22520141

Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (PRV), RotaTeq(®), 3 doses at approximately 6, 10, and 14 weeks of age
Number of subjects: 5468
Study: 20080470

Group type: EXPERIMENTAL
Intervention: Intensive use of lotion containing 3% urea, polidocanol, and hyaluronic acid
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard use of lotion containing 3% urea, polidocanol, and hyaluronic acid
Number of subjects: 98
Study: 18595261

Group type: EXPERIMENTAL
Intervention: Angiotensin‐converting enzyme inhibitors
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blockers
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Beta‐blockers
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Long‐acting calcium antagonists
Number of subjects: 370

Group type: COMPARATOR
Intervention: Doxazosin
Number of subjects: 370

Group type: COMPARATOR
Intervention: Terazosin
Number of subjects: 370

Group type: COMPARATOR
Intervention: Torasemide
Number of subjects: 370
Study: 15751264

Group type: EXPERIMENTAL
Intervention: Combined hormone therapy (estrogen-progestin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other treatment arms of the WHI (not specified)
Number of subjects: 0
Study: 11678968

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 3159

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 3159

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 3159

Group type: EXPERIMENTAL
Intervention: Degree of physical activity in men
Number of subjects: 3159

Group type: EXPERIMENTAL
Intervention: Age and HbA1c adjusted values
Number of subjects: 3159

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 3159

Group type: EXPERIMENTAL
Intervention: Total cholesterol, LDL-C, HDL-C and HDL-C subfractions
Number of subjects: 3159
Study: 9702849

Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study: 7526753

Group type: EXPERIMENTAL
Intervention: Neutrophils from clinically normal cows
Number of subjects: 46

Group type: COMPARATOR
Intervention: Neutrophils from cows with metritis
Number of subjects: 46

Group type: COMPARATOR
Intervention: Neutrophils from cows with mastitis
Number of subjects: 46

Group type: COMPARATOR
Intervention: Neutrophils from postparturient cows with abnormalities (retained placenta, metritis, mastitis)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Neutrophils preincubated alone in a 37 C water bath for 30 minutes
Number of subjects: 46
Study: 2644581

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1087732

Group type: EXPERIMENTAL
Intervention: Intravenous L-5-hydroxytryptophan (L-5HTP)
Number of subjects: 0
Study: 30664111

Group type: EXPERIMENTAL
Intervention: Combined surfaces plyometric jump training (PJTc)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Single-surface plyometric jump training (PJTs)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Active control (CON)
Number of subjects: 23
Study: 30346242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1183

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 1183

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 1183
Study: 27091535

Group type: EXPERIMENTAL
Intervention: Guided Internet‐based cognitive behavioral therapy for insomnia (ICBT‐i)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Active control treatment (ICBT‐ctrl)
Number of subjects: 148
Study: 24998105

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with S‐(+)‐ketamine (25mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 80
Study: 21494228

Group type: EXPERIMENTAL
Intervention: Lifestyle Change
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health Education
Number of subjects: 0
Study: 20515210

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (BMI)
Number of subjects: 1014

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (BMI) + Parent-based intervention (PBI)
Number of subjects: 1014
Study: 18175740

Group type: EXPERIMENTAL
Intervention: Whole-grain diet (hypocaloric, reduced by 500 kcal/d)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Refined-grain diet (hypocaloric, reduced by 500 kcal/d)
Number of subjects: 50
Study: 15794787

Group type: EXPERIMENTAL
Intervention: Oral desmopressin 400 microg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 14649310

Group type: EXPERIMENTAL
Intervention: cilnidipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: amlodipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: nifedipine CR
Number of subjects: 0
Study: 10980763

Group type: EXPERIMENTAL
Intervention: Follow-up visual fields with abnormalities (n = 748)
Number of subjects: 1637

Group type: EXPERIMENTAL
Intervention: Follow-up visual fields with unreliability (n = 258)
Number of subjects: 1637

Group type: EXPERIMENTAL
Intervention: Retesting of originally abnormal and reliable visual fields (n = 703)
Number of subjects: 1637
Study: 8784652

Group type: EXPERIMENTAL
Intervention: Zalospirone 45 mg/day
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Zalospirone 6 mg/day
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Zalospirone 15 mg/day
Number of subjects: 287

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study: 1733381

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 2046

Group type: EXPERIMENTAL
Intervention: Gemfibrozil (adjusted for other risk factors)
Number of subjects: 2046
Study: 6467858

Group type: EXPERIMENTAL
Intervention: Sodium fluoride (50 mg/day) combined with 25-50 micrograms of 25 OH cholecalciferol (calcifediol) per day for 6-18 months (12 patients) and 31-58 months (9 patients)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo for 6-18 months (9 patients)
Number of subjects: 19
Study: 30777658

Group type: EXPERIMENTAL
Intervention: Testes with grade I varicocele
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Testes with grade II varicocele
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Testes with grade III varicocele
Number of subjects: 30

Group type: COMPARATOR
Intervention: Contralateral testes with grade I varicocele
Number of subjects: 30

Group type: COMPARATOR
Intervention: Contralateral testes with grade II varicocele
Number of subjects: 30

Group type: COMPARATOR
Intervention: Contralateral testes with grade III varicocele
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Testes with varicocele (volume difference > 20%)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Contralateral testes (volume difference > 20%)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Testes with varicocele (volume difference 0-20%)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Contralateral testes (volume difference 0-20%)
Number of subjects: 30
Study: 29801402

Group type: EXPERIMENTAL
Intervention: Traditional health education program (THEP)
Number of subjects: 999

Group type: EXPERIMENTAL
Intervention: Tapping peer leaders using mobile phone prompts (PPHEP)
Number of subjects: 999

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 999
Study: 26497857

Group type: EXPERIMENTAL
Intervention: EHF1-3
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: EHF8
Number of subjects: 79
Study: 24112635

Group type: EXPERIMENTAL
Intervention: Intravitreal 0.5 mg ranibizumab
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard-of-care grid laser
Number of subjects: 36
Study: 22834417

Group type: EXPERIMENTAL
Intervention: Estradiol (E2) gel 1.5 mg and oral micronized progesterone (P) 200 mg/day for the last 14 days of each cycle
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral conjugated equine estrogens (CEE) 0.625 mg and oral medroxyprogesterone acetate (MPA) 5 mg for the last 14 days of each cycle
Number of subjects: 100
Study: 20601257

Group type: EXPERIMENTAL
Intervention: Intraoperative nerve monitoring (IONM)
Number of subjects: 237

Group type: COMPARATOR
Intervention: No IONM (visualization alone)
Number of subjects: 237
Study: 17662759

Group type: EXPERIMENTAL
Intervention: Adherence self-efficacy (ASE)
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Educational attainment (EA)
Number of subjects: 980
Study: 16099600

Group type: EXPERIMENTAL
Intervention: Balsalazide (2250 mg, twice daily for 5 days before RT and 2 weeks after completion)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (identical-appearing, twice daily for 5 days before RT and 2 weeks after completion)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Balsalazide
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 12237172

Group type: EXPERIMENTAL
Intervention: Healthy diet
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Vitamin C (1 g/day)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 10545746

Group type: EXPERIMENTAL
Intervention: Vitamin E supplement (100 mg orally daily) in addition to RRT
Number of subjects: 50

Group type: COMPARATOR
Intervention: RRT only
Number of subjects: 50
Study: 7562887

Group type: EXPERIMENTAL
Intervention: Hawksley random zero sphygmomanometer (RZS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard mercury sphygmomanometer (SMS)
Number of subjects: 24
Study: 3615572

Group type: EXPERIMENTAL
Intervention: Zuclopenthixol (37 mg daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Perphenazine (30 mg daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 40
Study: 30150750

Group type: EXPERIMENTAL
Intervention: 20 mg fluoxetine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 27070980

Group type: EXPERIMENTAL
Intervention: Team development intervention implemented in 4 of 5 clinics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 25271034

Group type: EXPERIMENTAL
Intervention: 15 degrees bed elevation
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: 30 degrees bed elevation
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: 45 degrees bed elevation
Number of subjects: 252

Group type: COMPARATOR
Intervention: Supine position (control group)
Number of subjects: 252
Study: 23734840

Group type: EXPERIMENTAL
Intervention: 1 g mesalazine suppository once daily for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo suppository once daily for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 g mesalazine suppository
Number of subjects: 0
Study: 20236174

Group type: EXPERIMENTAL
Intervention: FTLD-FUS
Number of subjects: 3

Group type: COMPARATOR
Intervention: FTLD-TDP
Number of subjects: 3

Group type: COMPARATOR
Intervention: FTLD-TAU
Number of subjects: 3
Study: 18420315

Group type: EXPERIMENTAL
Intervention: 11-valent pneumococcal conjugate vaccine with protein D of Haemophilus influenzae as a carrier (PncPD11)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 7-valent pneumococcal conjugate vaccine (PncCRM7)
Number of subjects: 0
Study: 19560968

Group type: EXPERIMENTAL
Intervention: 15m square shuttle run test (SST)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 20 m multistage shuttle run test (MST)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Treadmill test (TT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: SST
Number of subjects: 45
Study: 15805366

Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide (iNO)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control (no iNO)
Number of subjects: 108
Study: 12017793

Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dentin bonding agent alone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dentin bonding agent in combination with flowable composite
Number of subjects: 60

Group type: COMPARATOR
Intervention: Flowable compomer
Number of subjects: 60

Group type: COMPARATOR
Intervention: Autopolymerizing composite
Number of subjects: 60
Study: 9355815

Group type: EXPERIMENTAL
Intervention: Multi-family psycho-educational intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-EE key relatives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multi-family groups
Number of subjects: 0
Study: 7678686

Group type: EXPERIMENTAL
Intervention: Cibenzoline (130-390 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sotalol (160-320 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control state
Number of subjects: 12
Study: 3309186

Group type: EXPERIMENTAL
Intervention: Imipramine and self-exposure
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo and self-exposure
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 40
Study: 11838820

Group type: EXPERIMENTAL
Intervention: Risperidone (short-term, placebo-controlled study)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risperidone (extended open-label maintenance)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (placebo-controlled discontinuation study)
Number of subjects: 0
Study: 30361113

Group type: EXPERIMENTAL
Intervention: RM12 (12 cmH2O PEEP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: RM17 (17 cmH2O PEEP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: RM7 (7 cmH2O PEEP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (7 cmH2O PEEP)
Number of subjects: 30